Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma

Conclusion: Treatment with mepolizumab is associated with an attenuated symptom response to prednisolone treatment in severe eosinophilic asthma via a mechanism that is likely to be independent of changes in airflow limitation.

Source: European Respiratory Journal - December 6, 2017 Category: Respiratory Medicine Authors: Shrimanker, R., Hargaden, B., Bradding, P., Wardlaw, A., Brightling, C., Green, R., Bafadhel, M., Heaney, L., Pavord, I., Haldar, P. Tags: Airway Pharmacology and Treatment Source Type: research